SG Americas Securities LLC Grows Position in Nektar Therapeutics (NASDAQ:NKTR)

SG Americas Securities LLC increased its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 30.4% during the third quarter, Holdings Channel reports. The institutional investor owned 95,637 shares of the biopharmaceutical company’s stock after buying an additional 22,285 shares during the quarter. SG Americas Securities LLC’s holdings in Nektar Therapeutics were worth $124,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. Samlyn Capital LLC purchased a new stake in shares of Nektar Therapeutics during the second quarter worth approximately $11,728,000. Millennium Management LLC increased its stake in Nektar Therapeutics by 56.1% in the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after purchasing an additional 1,674,924 shares during the last quarter. Nantahala Capital Management LLC increased its stake in Nektar Therapeutics by 66.0% in the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock valued at $5,096,000 after purchasing an additional 1,634,046 shares during the last quarter. Lynx1 Capital Management LP increased its stake in Nektar Therapeutics by 7.2% in the first quarter. Lynx1 Capital Management LP now owns 2,068,842 shares of the biopharmaceutical company’s stock valued at $1,933,000 after purchasing an additional 139,644 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in Nektar Therapeutics in the second quarter valued at approximately $1,037,000. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Trading Down 2.2 %

Shares of NKTR opened at $1.32 on Friday. The firm has a market cap of $242.99 million, a PE ratio of -1.47 and a beta of 0.60. The company’s 50 day simple moving average is $1.28 and its 200-day simple moving average is $1.35. Nektar Therapeutics has a 12-month low of $0.41 and a 12-month high of $1.93.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). The business had revenue of $23.49 million for the quarter, compared to analysts’ expectations of $17.24 million. Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. During the same quarter last year, the business posted ($0.27) earnings per share. As a group, equities research analysts forecast that Nektar Therapeutics will post -0.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, BTIG Research reiterated a “buy” rating and issued a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday, September 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Nektar Therapeutics presently has a consensus rating of “Hold” and an average target price of $2.33.

Nektar Therapeutics Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.